Net sales for the third quarter of the fiscal year ending March 2026 amounted to \u00a5215.14 billion (YoY increase of 3.8%), operating income was \u00a58.887 billion (YoY increase of 16.4%), and net income attributable to owners of parent for the quarter was \u00a56.578 billion (YoY increase of 19.9%).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4975","jir_company_name":"JCU Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4975-20260205-01.pdf","jir_short_summary":"Net sales for the third quarter of the fiscal year ending March 2026 amounted to \u00a5215.14 billion (YoY increase of 3.8%), operating income was \u00a58.887 billion (YoY increase of 16.4%), and net income attributable to owners of parent for the quarter was \u00a56.578 billion (YoY increase of 19.9%).","jir_summary":"### Overview of Financial Results\nFor the cumulative third quarter period of the fiscal year ending March 2026, consolidated net sales were \u00a521,514 million (3.8% increase YoY), operating income was \u00a58,887 million (16.4% increase YoY), ordinary income was \u00a59,003 million (13.2% increase YoY), and net income attributable to owners of parent for the quarter was \u00a56,578 million (19.9% increase YoY). Amid a gradual recovery trend in the domestic and global economic environment, demand in the electronic components sector remained robust, particularly boosted by increased demand in the electronic industries of China, Taiwan, and South Korea. Conversely, in the decorative sector, pharmaceutical demand remained flat in Japan and China, and there was an impact from decreased demand in automotive parts. The equipment business saw declines in net sales and profit due to a reduction in large-scale projects.\n\n### Financial Position and Dividends\nTotal assets increased to \u00a555,922 million (an increase of \u00a51,081 million from the end of the previous fiscal year), and net assets rose to \u00a551,071 million (an increase of \u00a53,258 million), with an improved equity ratio of 91.3%. Regarding dividends, the forecasted annual dividend for the fiscal year ending March 2026 has been revised upwards to \u00a595 per share (from \u00a576 previously). The company holds 1,830,926 shares of treasury stock (1,608,714 shares at the end of the previous fiscal year), has disposed of 9,536 shares under restricted stock compensation, and the treasury stock amounts to \u00a55,986 million.\n\n### Outlook\nThe full-year earnings forecast for the fiscal year ending March 2026 anticipates net sales of \u00a529,200 million (YoY increase of 3.0%), operating income of \u00a511,600 million (YoY increase of 10.3%), ordinary income of \u00a511,800 million (YoY increase of 8.1%), and net income attributable to owners of parent of \u00a58,500 million (YoY increase of 13.4%). This forecast incorporates expected growth in the pharmaceutical products for the electronic sector and the semiconductor-related market while factoring in subdued demand in the decorative sector. Based on the medium-term management plan 'JCU VISION 2035 -1st stage-', the company intends to continue active investments in growth areas and strengthen its management foundation.","jir_financial_highlights":"Net Sales: \u00a521,514 million (YoY increase of 3.8%)\nOperating Income: \u00a58,887 million (YoY increase of 16.4%)\nOrdinary Income: \u00a59,003 million (YoY increase of 13.2%)\nNet Income Attributable to Owners of Parent for the Quarter: \u00a56,578 million (YoY increase of 19.9%)\nEquity Ratio: 91.3% (Improved from 87.2% in the previous corresponding period)\nAnnual Dividend (Forecast): \u00a595 (Planned increase from \u00a576 in the previous fiscal year)\nFull-Year Earnings Guidance Net Sales: \u00a529,200 million (YoY increase of 3.0%)\nFull-Year Earnings Guidance Operating Income: \u00a511,600 million (YoY increase of 10.3%)\nFull-Year Earnings Guidance Net Income Attributable to Owners of Parent: \u00a58,500 million (YoY increase of 13.4%)","jir_category":"","jir_hashtags":"#JCUCorporation, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales (Cumulative Third Quarter): \u00a521,514 million (YoY increase of 3.8%)\nOperating Income (Cumulative Third Quarter): \u00a58,887 million (YoY increase of 16.4%)\nNet Income Attributable to Owners of Parent for the Quarter: \u00a56,578 million (YoY increase of 19.9%)","jir_meta_title":"JCU Corporation Financial Summary for Third Quarter Ending March 2026 - Net Sales \u00a5215.14 Billion, Operating Income Up 16.4%","jir_meta_description":"JCU Corporation's financial summary for the third quarter of the fiscal year ending March 2026. Net sales of \u00a521,514 million (up 3.8% YoY), operating income of \u00a58,887 million (up 16.4%), and net income attributable to owners of parent of \u00a56,578 million (up 19.9%). Dividend forecast increased to \u00a595.","jir_og_title":"JCU Corporation Announces Financial Summary for Third Quarter Ending March 2026","jir_og_description":"JCU Corporation announced its financial summary for the third quarter ending March 2026, achieving higher net sales of \u00a521,514 million, operating income of \u00a58,887 million, and net income of \u00a56,578 million.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Cumulative Q3\\\",\\\"2026 Cumulative Q3\\\",\\\"2026 Full Year Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[20732,21514,29200],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Cumulative Q3\\\",\\\"2026 Cumulative Q3\\\",\\\"2026 Full Year Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[7636,8887,11600],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent for the Quarter Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Cumulative Q3\\\",\\\"2026 Cumulative Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[5487,6578],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals Business\\\",\\\"Equipment Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"2025 Cumulative Q3\\\",\\\"data\\\":[17812,2920],\\\"backgroundColor\\\":\\\"#007bff\\\"},{\\\"label\\\":\\\"2026 Cumulative Q3\\\",\\\"data\\\":[19505,2008],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_profit_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profit (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals Business\\\",\\\"Equipment Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"2025 Cumulative Q3\\\",\\\"data\\\":[7904,421],\\\"backgroundColor\\\":\\\"#007bff\\\"},{\\\"label\\\":\\\"2026 Cumulative Q3\\\",\\\"data\\\":[9321,298],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":9340,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-24648","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n